Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2008

01.02.2008 | Review Article

Chronic kidney disease perspectives in Japan and the importance of urinalysis screening

verfasst von: Kunihiro Yamagata, Kunitoshi Iseki, Kousaku Nitta, Hirokazu Imai, Yasuhiko Iino, Seiichi Matsuo, Hirofumi Makino, Akira Hishida

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

There are racial differences in primary renal diseases for end-stage renal disease (ESRD) and the incidence and prevalence of cardiovascular disease (CVD). To reduce the number of patients with both ESRD and CVD, an effective screening method for CKD should be established. In Japan, screening with the urine dip-stick test for proteinuria has been used since 1972 targeting every child and worker and since 1983 for every resident over 40 years old. There are several reasons for continuing this screening program. First, the positive rate of proteinuria is high in the Japanese general population, especially subjects with neither hypertension nor diabetes. Most of these subjects have no symptoms, and the only sign of renal disease is asymptomatic urinary abnormalities. Second, the prevalence and incidence of glomerulonephritis, especially IgA nephropathy, are high in the Japanese and Asian races, and urinalysis is the only method for early detection of chronic glomerulonephritis. Third, 10-year survival of the ESRD patients due to glomerulonephritis was approximately twice that of ESRD patients due to diabetes and nephrosclerosis. Consequently, reducing the incidence of ESRD due to glomerulonephritis is one of the best ways to reduce the prevalence of ESRD. Furthermore, higher incidence of ESRD in Asian races than in Caucasians was reported. Proteinuria is known to be the best predictor for reducing renal function, and the urine dip-stick test for proteinuria is less expensive and is cost-effective. For an effective screening strategy to reduce the ESRD population in Japanese and Asians, universal screening with the urine dip-stick test for proteinuria could be one solution.
Literatur
1.
Zurück zum Zitat Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–8.PubMed Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12:2753–8.PubMed
2.
Zurück zum Zitat Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37–40.PubMed Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(Suppl 1):S37–40.PubMed
3.
Zurück zum Zitat Nakai S, Masagane I, Akiba T, Iseki K, Watanabe Y, Itami Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2005). J Jpn Soc Dial Ther. 2007;40:1–30.CrossRef Nakai S, Masagane I, Akiba T, Iseki K, Watanabe Y, Itami Y, et al. An overview of dialysis treatment in Japan (as of Dec. 31, 2005). J Jpn Soc Dial Ther. 2007;40:1–30.CrossRef
4.
Zurück zum Zitat Systems USRD: USRDS 2006 Annual Data Report. Bethesda: National Institute of Health; 2007. Systems USRD: USRDS 2006 Annual Data Report. Bethesda: National Institute of Health; 2007.
5.
Zurück zum Zitat Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64:1903–10.CrossRefPubMed Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003;64:1903–10.CrossRefPubMed
6.
Zurück zum Zitat K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:76–110.CrossRef K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;39:76–110.CrossRef
7.
Zurück zum Zitat Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed
8.
Zurück zum Zitat Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed
9.
Zurück zum Zitat Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. 2005;67(Suppl 98):S7–10.CrossRef Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. 2005;67(Suppl 98):S7–10.CrossRef
10.
Zurück zum Zitat Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906.CrossRefPubMed Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853–906.CrossRefPubMed
11.
Zurück zum Zitat Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRefPubMed Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRefPubMed
12.
Zurück zum Zitat Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.CrossRefPubMed Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–15.CrossRefPubMed
13.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
14.
Zurück zum Zitat Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.CrossRefPubMed Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.CrossRefPubMed
15.
Zurück zum Zitat Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66:1310–4.CrossRefPubMed Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. Kidney Int. 2004;66:1310–4.CrossRefPubMed
16.
Zurück zum Zitat Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;70:2058–65.CrossRefPubMed Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;70:2058–65.CrossRefPubMed
17.
Zurück zum Zitat Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–65.CrossRefPubMed Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35:157–65.CrossRefPubMed
18.
Zurück zum Zitat Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994–2004. MMWR Morb Mortal Wkly Rep. 2007;56:253–6. Racial differences in trends of end-stage renal disease, by primary diagnosis-United States, 1994–2004. MMWR Morb Mortal Wkly Rep. 2007;56:253–6.
19.
Zurück zum Zitat Hemmelgarn BR, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, et al. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada. Am J Kidney Dis. 2006;48:964–71.CrossRefPubMed Hemmelgarn BR, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, et al. Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada. Am J Kidney Dis. 2006;48:964–71.CrossRefPubMed
20.
Zurück zum Zitat Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis. 2004;43:433–43.CrossRefPubMed Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis. 2004;43:433–43.CrossRefPubMed
21.
Zurück zum Zitat World Health Organization: World Health Statistics 2006, 2007. World Health Organization: World Health Statistics 2006, 2007.
22.
Zurück zum Zitat Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation. 2001;103:462–8.CrossRefPubMed Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part I: morbidity and mortality monitoring. Circulation. 2001;103:462–8.CrossRefPubMed
23.
Zurück zum Zitat Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002;91:34–42.CrossRefPubMed Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002;91:34–42.CrossRefPubMed
24.
Zurück zum Zitat Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119 985 adults over three years. QJM. 2001;94:541–50.CrossRefPubMed Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119 985 adults over three years. QJM. 2001;94:541–50.CrossRefPubMed
25.
Zurück zum Zitat Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA. 1989;262:1214–9.CrossRefPubMed Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. JAMA. 1989;262:1214–9.CrossRefPubMed
27.
Zurück zum Zitat Caskey FJ, Schober-Halstenberg HJ, Roderick PJ, Edenharter G, Ansell D, Frei U, et al. Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis. 2006;47:445–54.CrossRefPubMed Caskey FJ, Schober-Halstenberg HJ, Roderick PJ, Edenharter G, Ansell D, Frei U, et al. Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis. 2006;47:445–54.CrossRefPubMed
29.
Zurück zum Zitat Stewart JH, McCredie M, Disney AP, Mathew TH. Trends in incidence of end-stage renal failure in Australia, 1972–1991. Nephrol Dial Transplant. 1994;9:1377–82.PubMed Stewart JH, McCredie M, Disney AP, Mathew TH. Trends in incidence of end-stage renal failure in Australia, 1972–1991. Nephrol Dial Transplant. 1994;9:1377–82.PubMed
30.
Zurück zum Zitat Wimmer F, Oberaigner W, Kramar R, Mayer G. Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant. 2003;18:1562–7.CrossRefPubMed Wimmer F, Oberaigner W, Kramar R, Mayer G. Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant. 2003;18:1562–7.CrossRefPubMed
31.
Zurück zum Zitat Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46–55.CrossRefPubMed Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49:46–55.CrossRefPubMed
32.
Zurück zum Zitat Tiebosch ATMG, Wolters J, Frederik PFM, van der Wiel TWM, Zeppenfeldt E, van Breda Vriesman PJC. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int. 1987;32:112–6.CrossRefPubMed Tiebosch ATMG, Wolters J, Frederik PFM, van der Wiel TWM, Zeppenfeldt E, van Breda Vriesman PJC. Epidemiology of idiopathic glomerular disease: a prospective study. Kidney Int. 1987;32:112–6.CrossRefPubMed
33.
Zurück zum Zitat Simon P, Ramee MP, Autuly V, Laruelle E, Charasse C, Cam G, et al. Epidemiology of primary glomerular diseases in a Frecnch region. Variations according to period of age. Kidney Int. 1994;46:1192–8.CrossRefPubMed Simon P, Ramee MP, Autuly V, Laruelle E, Charasse C, Cam G, et al. Epidemiology of primary glomerular diseases in a Frecnch region. Variations according to period of age. Kidney Int. 1994;46:1192–8.CrossRefPubMed
34.
Zurück zum Zitat Koyama A, Igarashi M, Kobayashi M. Naturals history and risk factors for immunoglobulin A nephropathy. Am J Kid Dis. 1997;29:526–32.CrossRefPubMed Koyama A, Igarashi M, Kobayashi M. Naturals history and risk factors for immunoglobulin A nephropathy. Am J Kid Dis. 1997;29:526–32.CrossRefPubMed
35.
Zurück zum Zitat Cameron JS. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 1990;1:81–7.CrossRef Cameron JS. Proteinuria and progression in human glomerular diseases. Am J Nephrol. 1990;1:81–7.CrossRef
36.
Zurück zum Zitat Cameron JS. The long-term outcome of glomerular diseases. 6th ed. Boston/Tronto/London: Little Brown and Company;1997. Cameron JS. The long-term outcome of glomerular diseases. 6th ed. Boston/Tronto/London: Little Brown and Company;1997.
37.
Zurück zum Zitat Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed
38.
Zurück zum Zitat Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K, et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med. 2001;40:697–702.CrossRefPubMed Usui J, Yamagata K, Kai H, Outeki T, Yamamoto S, Muro K, et al. Heterogeneity of prognosis in adult IgA nephropathy, especially with mild proteinuria or mild histological features. Intern Med. 2001;40:697–702.CrossRefPubMed
39.
Zurück zum Zitat Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35:S97–105.CrossRefPubMed Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35:S97–105.CrossRefPubMed
40.
Zurück zum Zitat Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–96.CrossRefPubMedPubMedCentral Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–96.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.CrossRefPubMed Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–35.CrossRefPubMed
42.
Zurück zum Zitat Nagai R, Wang EEL, Feldman W. Dipstick proteinuria screening of asymptomatic adults to prevent progressive renal disease. In: Canadian Task Force on the Periodic Health Examination. Otawa: Health Canada; 1994. Nagai R, Wang EEL, Feldman W. Dipstick proteinuria screening of asymptomatic adults to prevent progressive renal disease. In: Canadian Task Force on the Periodic Health Examination. Otawa: Health Canada; 1994.
43.
Zurück zum Zitat Murakami M, Hayakawa M, Yanagihara T, Hukunaga Y. Proteinuria screening for children. Kidney Int Suppl. 2005; 67:S23–7.CrossRef Murakami M, Hayakawa M, Yanagihara T, Hukunaga Y. Proteinuria screening for children. Kidney Int Suppl. 2005; 67:S23–7.CrossRef
44.
Zurück zum Zitat D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Quart J Med. 1987;64:709–27.PubMed D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Quart J Med. 1987;64:709–27.PubMed
45.
Zurück zum Zitat Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006;69:1455–8.CrossRefPubMed Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006;69:1455–8.CrossRefPubMed
46.
Zurück zum Zitat Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–52.CrossRefPubMed Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–52.CrossRefPubMed
47.
Zurück zum Zitat Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–5.CrossRefPubMed Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–5.CrossRefPubMed
48.
Zurück zum Zitat Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–7.CrossRefPubMed
49.
Zurück zum Zitat Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000;35:194–201.CrossRefPubMed Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis. 2000;35:194–201.CrossRefPubMed
50.
Zurück zum Zitat Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736–43.CrossRefPubMed
51.
Zurück zum Zitat Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.CrossRefPubMed Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63:1861–7.CrossRefPubMed
52.
Zurück zum Zitat Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRefPubMed Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRefPubMed
53.
Zurück zum Zitat Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–75.CrossRefPubMed Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–75.CrossRefPubMed
54.
Zurück zum Zitat Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed
55.
Zurück zum Zitat Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRefPubMed Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRefPubMed
56.
Zurück zum Zitat Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol. 1996;45:281–8.PubMed Yamagata K, Yamagata Y, Kobayashi M, Koyama A. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol. 1996;45:281–8.PubMed
57.
Zurück zum Zitat Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907–17.CrossRefPubMed Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907–17.CrossRefPubMed
58.
Zurück zum Zitat Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed
59.
Zurück zum Zitat Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333:1047.CrossRefPubMedPubMedCentral Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et al. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006;333:1047.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch–European diabetic patients. Diabetes Care. 2006;29:1383–5.CrossRefPubMed Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch–European diabetic patients. Diabetes Care. 2006;29:1383–5.CrossRefPubMed
61.
Zurück zum Zitat Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med. 1992;9:641–5.CrossRefPubMed Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med. 1992;9:641–5.CrossRefPubMed
62.
Zurück zum Zitat Lightstone L, Rees AJ, Tomson C, Walls J, Winearls CG, Feehally J. High incidence of end-stage renal disease in Indo-Asians in the UK. QJM. 1995;88:191–5.PubMed Lightstone L, Rees AJ, Tomson C, Walls J, Winearls CG, Feehally J. High incidence of end-stage renal disease in Indo-Asians in the UK. QJM. 1995;88:191–5.PubMed
63.
Zurück zum Zitat Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56:1577–85.CrossRefPubMed Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). Diabetes. 2007;56:1577–85.CrossRefPubMed
64.
Zurück zum Zitat Trehan A, Winterbottom J, Lane B, Foley R, Venning M, Coward R, et al. End-stage renal disease in Indo-Asians in the North-West of England. QJM. 2003;96:499–504.CrossRefPubMed Trehan A, Winterbottom J, Lane B, Foley R, Venning M, Coward R, et al. End-stage renal disease in Indo-Asians in the North-West of England. QJM. 2003;96:499–504.CrossRefPubMed
65.
Zurück zum Zitat Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22–35.CrossRefPubMed Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2003;42:22–35.CrossRefPubMed
66.
Zurück zum Zitat McGill JB, Brown WW, Chen SC, Collins AJ, Gannon MR. Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ. 2004;30:196–8 (200–192, 206).CrossRefPubMed McGill JB, Brown WW, Chen SC, Collins AJ, Gannon MR. Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ. 2004;30:196–8 (200–192, 206).CrossRefPubMed
67.
Zurück zum Zitat Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.CrossRefPubMed Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–84.CrossRefPubMed
68.
Zurück zum Zitat Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.CrossRefPubMed Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.CrossRefPubMed
69.
Zurück zum Zitat Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.CrossRefPubMed Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.CrossRefPubMed
70.
Zurück zum Zitat Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.CrossRefPubMed Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.CrossRefPubMed
71.
Zurück zum Zitat Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189–98.CrossRefPubMed Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol. 2004;33:189–98.CrossRefPubMed
72.
Zurück zum Zitat Dell’Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1–8.CrossRefPubMed Dell’Omo G, Penno G, Giorgi D, Di Bello V, Mariani M, Pedrinelli R. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1–8.CrossRefPubMed
73.
Zurück zum Zitat Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet. 2005;365:556–7.CrossRefPubMed Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet. 2005;365:556–7.CrossRefPubMed
74.
Zurück zum Zitat de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109–18.CrossRefPubMed de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004;66:2109–18.CrossRefPubMed
75.
Zurück zum Zitat Konta T, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006;70:751–6.CrossRefPubMed Konta T, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006;70:751–6.CrossRefPubMed
76.
Zurück zum Zitat Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant. 2007. Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin creatinine ratio and urine albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant. 2007.
77.
Zurück zum Zitat de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–7.CrossRefPubMed de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921–7.CrossRefPubMed
78.
Zurück zum Zitat de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.CrossRefPubMed de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–20.CrossRefPubMed
79.
Zurück zum Zitat Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol. 2007;18:1540–6.CrossRefPubMed Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol. 2007;18:1540–6.CrossRefPubMed
80.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed
81.
Zurück zum Zitat Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40.CrossRefPubMed Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–40.CrossRefPubMed
Metadaten
Titel
Chronic kidney disease perspectives in Japan and the importance of urinalysis screening
verfasst von
Kunihiro Yamagata
Kunitoshi Iseki
Kousaku Nitta
Hirokazu Imai
Yasuhiko Iino
Seiichi Matsuo
Hirofumi Makino
Akira Hishida
Publikationsdatum
01.02.2008
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2008
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-007-0010-9

Weitere Artikel der Ausgabe 1/2008

Clinical and Experimental Nephrology 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.